Xiaotong Yu1, Liping Liu1, Zhenwei Xie2, Chongya Dong3, Libo Zhao4, Jingru Zhang1, Jian Gu5, Hong-Hu Zhu6. 1. Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. 2. Department of Scientific Research, Peking University People's Hospital, Beijing, 100044, China. 3. Peking University First Hospital, Beijing, 100034, China. 4. Department of Pharmacy, Beijing Children's Hospital Affiliated to Capital University of Medical Sciences, Beijing, 100045, China. 5. Department of Pharmacy, Peking University People's Hospital, Beijing, 100044, China. Electronic address: gujian201302@sina.cn. 6. Department of Hematology & Institute of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310003, China. Electronic address: zhuhhdoc@163.com.
Abstract
BACKGROUND: Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT, particularly for patients using post-transplant cyclophosphamide (PTCy), which is the standard therapy. However, to date, no meta-analysis focusing on this issue has been published. METHODS: We systematically searched PubMed, MEDLINE, Web of Science, the Cochrane Library and the ClinicalTrials.gov website for studies regarding the use of BM or PB in haploidentical HSCT for hematological malignancies in adults using PTCy. Data were analyzed using Open Meta-Analyst statistical software. RESULTS: Fourteen studies were extracted including four comparative retrospective reports and ten single-arm reports, with a total of 1759 patients received PTCy haploidentical HSCT (462 patients received PBSCT, 1297 patients received BMT). The pooled outcomes of comparative retrospective studies showed significantly higher incidence of grade III-IV acute graft-versus-host disease (GVHD) (OR = 1.741, 95%CI 1.032-2.938), incidence of grade IIIV acute GVHD (OR = 1.778, 95%CI 1.314, 2.406) and engraftment rate (OR = 1.843, 95%CI 1.066-3.185) in the PB group. No significant differences were found on the incidence of relapse, 2-year overall survival (OS) and disease-free survival (DFS), acute IIIV GVHD and chronic GVHD between PBSCT or BMT. CONCLUSION: The efficacy of PB is not inferior to BM for patients undergoing PTCy haploidentical HSCT with regard to primary outcomes, including OS, DFS, NRM and relapse. However, with regards to convenience and pain relief, PB graft is suitable for haploidentical HSCT, but with a higher risk of acute GVHD.
BACKGROUND: Peripheral-blood (PB) and bone marrow (BM) are both widely used in hematopoietic stem cell transplantation (HSCT). However, it is unclear whether PB or BM produces a more satisfactory outcome in haploidentical HSCT, particularly for patients using post-transplant cyclophosphamide (PTCy), which is the standard therapy. However, to date, no meta-analysis focusing on this issue has been published. METHODS: We systematically searched PubMed, MEDLINE, Web of Science, the Cochrane Library and the ClinicalTrials.gov website for studies regarding the use of BM or PB in haploidentical HSCT for hematological malignancies in adults using PTCy. Data were analyzed using Open Meta-Analyst statistical software. RESULTS: Fourteen studies were extracted including four comparative retrospective reports and ten single-arm reports, with a total of 1759 patients received PTCy haploidentical HSCT (462 patients received PBSCT, 1297 patients received BMT). The pooled outcomes of comparative retrospective studies showed significantly higher incidence of grade III-IV acute graft-versus-host disease (GVHD) (OR = 1.741, 95%CI 1.032-2.938), incidence of grade IIIV acute GVHD (OR = 1.778, 95%CI 1.314, 2.406) and engraftment rate (OR = 1.843, 95%CI 1.066-3.185) in the PB group. No significant differences were found on the incidence of relapse, 2-year overall survival (OS) and disease-free survival (DFS), acute IIIV GVHD and chronic GVHD between PBSCT or BMT. CONCLUSION: The efficacy of PB is not inferior to BM for patients undergoing PTCy haploidentical HSCT with regard to primary outcomes, including OS, DFS, NRM and relapse. However, with regards to convenience and pain relief, PB graft is suitable for haploidentical HSCT, but with a higher risk of acute GVHD.
Authors: Nidhi Sharma; Muhammad Salman Faisal; Qiuhong Zhao; Justin Jiang; Patrick Elder; Don M Benson; Ashley Rosko; Maria Chaudhry; Naresh Bumma; Abdullah Khan; Srinivas Devarakonda; Sumithira Vasu; Samantha Jaglowski; Alice S Mims; Hannah Choe; Karilyn Larkin; Jonathan E Brammer; Sarah Wall; Nicole Grieselhuber; Ayman Saad; Sam Penza; Audrey M Sigmund; Yvonne A Efebera Journal: J Clin Med Date: 2021-06-27 Impact factor: 4.241
Authors: Mohamad Mohty; Florent Malard; Manuel Abecasis; Erik Aerts; Ahmed S Alaskar; Mahmoud Aljurf; Mutlu Arat; Peter Bader; Frederic Baron; Grzegorz Basak; Ali Bazarbachi; Didier Blaise; Fabio Ciceri; Selim Corbacioglu; Jean-Hugues Dalle; Fiona Dignan; Takahiro Fukuda; Anne Huynh; Jurgen Kuball; Silvy Lachance; Hillard Lazarus; Tamas Masszi; Mauricette Michallet; Arnon Nagler; Mairead NiChonghaile; Shinichiro Okamoto; Antonio Pagliuca; Christina Peters; Finn B Petersen; Paul G Richardson; Tapani Ruutu; Wael Saber; Bipin N Savani; Robert Soiffer; Jan Styczynski; Elisabeth Wallhult; Ibrahim Yakoub-Agha; Rafael F Duarte; Enric Carreras Journal: Bone Marrow Transplant Date: 2019-10-01 Impact factor: 5.483
Authors: Yuebin Lin; Ya Yang; Yongjuan Zhao; Fan Gao; Xin Guo; Minhui Yang; Qingxiang Hong; Zhongmei Yang; Juan Dai; Changjiang Pan Journal: J Mater Sci Mater Med Date: 2021-03-06 Impact factor: 3.896